StockUS listing USAZRNASDAQHealthcareCapital Destroyer

Azora Therapeutics, Inc.(AZR) Stock Analysis | Healthcare

USD --+0.00%
Reward36Moderate
Risk27Low
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 55.00M
Reward Ratingⓘ36 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ27 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on AZR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Azora Therapeutics, Inc.?

operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases.

AI Brief Pro

The brief on Azora Therapeutics, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Azora Therapeutics, Inc.?

operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 55.00M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)
Company Information
SectorHealthcare
IndustryBiotechnology
BetaN/A
Insider Activity
12M windowNo data
No insider activity data available for this ticker.